Dataset Information

GNPS - Dataset Creation from GNPS Molcular Networking - 6bd4f858a8704e3fa98cb0c66de02248

ABSTRACT: 20 Methanol extracts of the hosts/endosclerotia of multiple species of the fungal genus Paraisaria (Ophiocordycipitaceae, Hypocreales). ID codes for the LCMS samples correspond to vouchered specimens as follows: En-1 = OSC-M-052011 En-2 = OSC-M-052009 En-3 = OSC-M-052008 En-4 = OSC-M-052005 En-5 = OSC-M-052007 En-6 = OSC-M-052015 En-8 = OSC-M-052017 En-9 = OSC-M-052016 En-10 = OSC-M-052012 En-11 = K-M 1434269 En-12 = OSC.164134 En-13 = OSC-M-052010 En-14 = OSC-M-052026 En-15 = OSC-M-052013 En-16 = OSC.164137 En-17 = OSC.164135 En-18 = OSC-M-052004 En-19 = OSC-M-052022 En-20 = OSC-M-052020 En-21 = BPI 634610

INSTRUMENT(S): 6545 Q-TOF LC/MS

ORGANISM(S): Paraisaria Spp.

SUBMITTER: Kerry McPhail

PROVIDER: MSV000092591 | GNPS | Thu Aug 03 14:28:00 BST 2023

REPOSITORIES: GNPS

ACCESS DATA

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Project description:We analyzed mutations in Epidermal Growth Factor Receptor (EGFR) Tyrosine kinase (TK) domain, EGFR expression and gene profiling in prostate carcinoma (PC) in order to find out molecular prognostic markers and supply a proof for EGFR targeted therapies. 100 glyofixx-fixed, paraffin-embedded PC specimens were recovered after radical prostatectomy from locally advanced PC patients. Exons from 18 to 21 of EGFR TK domain were amplified and sequenced. For the entire cohort, EGFR protein evaluation by immunohistochemistry was performed. Gene expression profile was analyzed on 51 out of 100 samples by whole genome microarray. Statistical tests were performed in order to detect any significant association between EGFR iperexpression and prognosis. None out of 100 specimens presented mutations in exon 18; 2 point mutations were identified in exon 19, 5 in exon 20 and 6 in exon 21. In addiction, 58 out of 100 patients had the same silent mutation, at codon 787 in exon 20. EGFR iper-expression was found in 36% of specimens and was significantly associated with biochemical relapse. Gene profiling analysis on mutated samples selected 29 modulated genes differentially expressed between mutated EGFR+ and mutated EGFR- samples; 4 down-regulated genes, EAF2, ABCC4, KLK3 and ANXA3 and one up-regulated gene, FOXC1, are involved in prostate cancer progression. Our findings suggest that a subgroup of PC patients could potentially benefit of EGFR targeted therapies. The EGFR protein evaluation could contribute to identify PC relapsers. Keywords: EGFR expression, TK mutations, target therapy, microarray data. In this work we studied mutation status and expression of Epidermal Growth Factor Receptor (EGFR) in a case series of 100 primary prostate cancer tissue specimens. Results indicate that 13% and 36% of PC patients presents EGFR tyrosine kinase domain mutations and iperexpression respectively, suggesting that this receptor could be a therapeutic target in progressive prostate cancer. The analysis of correlation between EGFR protein expression, mutations, clinical parameters and outcome allow us to identify EGFR as significantly associated with biochemical relapse and high Gleason score. Gene expression profiling in 51 of PC tissues led to the identification of a gene list which separated EGFR mutated patients according to EGFR protein expression. These results could give more information on clinical outcome and possible development of new targeted therapies.

Dataset Information

GNPS - Dataset Creation from GNPS Molcular Networking - 6bd4f858a8704e3fa98cb0c66de02248

Dataset's files

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets